- ISIN
- US36338D1081
- CUSIP
- 36338D108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 7, 2019
Highlights
- Market Cap
- $8.93M
- Enterprise Value
- $3.43M
- EPS (TTM)
- $1.51
- PE Ratio
- 0.06
- EBITDA (TTM)
- -$5.69M
- Year Range
- $0.02 - $0.15
- ROA (TTM)
- 2,417.83%
- ROE (TTM)
- 2,967.05%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GRTX Performance Chart
Galera Therapeutics, Inc. (GRTX) is up 311.6% since the beginning of the year. At $0 per share, GRTX is trading 39.6% below its 52-week high of $0. Investors who bought $1,000 worth of GRTX shares 5 years ago would now be looking at an investment worth $10.
Loading charts...
Returns By Period
Galera Therapeutics, Inc. (GRTX) has returned 311.59% so far this year and 223.39% over the past 12 months.
Galera Therapeutics, Inc.
- 1D
- 5.66%
- 1M
- -9.54%
- YTD
- 311.59%
- 6M
- 321.63%
- 1Y
- 223.39%
- 3Y*
- -67.91%
- 5Y*
- -60.09%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GRTX Monthly Returns History
Based on dividend-adjusted daily data since Nov 7, 2019, GRTX's average daily return is +0.05%, while the average monthly return is +2.04%. At this rate, an investment would double in approximately 2.9 years.
Historically, 46% of months were positive and 54% were negative. The best month was Dec 2021 with a return of +247.7%, while the worst month was Aug 2023 at -91.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, GRTX closed higher 44% of trading days. The best single day was Dec 14, 2021 with a return of +95.7%, while the worst single day was Aug 10, 2023 at -83.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.64% | 121.70% | -4.26% | 122.22% | 0.00% | -9.45% | 311.59% | ||||||
| 2025 | -3.93% | -12.95% | -21.67% | -26.33% | 12.49% | 9.41% | -11.76% | -16.67% | -11.50% | 52.54% | -20.37% | 2.33% | -51.97% |
| 2024 | 23.11% | 35.75% | -42.39% | 33.07% | 15.46% | -36.40% | -11.48% | -45.58% | 9.26% | -32.64% | -21.65% | 20.53% | -68.50% |
| 2023 | 64.43% | -27.76% | 44.63% | 6.64% | 12.45% | 1.63% | -21.15% | -91.46% | -16.62% | -44.55% | 46.76% | 2.04% | -90.24% |
| 2022 | -40.31% | -18.25% | 6.25% | -28.99% | -5.33% | -18.75% | -10.77% | 15.52% | 29.85% | -16.67% | 13.79% | -9.70% | -67.54% |
| 2021 | 9.87% | -6.67% | -15.92% | -7.60% | 5.15% | 14.70% | -14.75% | 6.92% | -9.60% | -76.91% | -29.41% | 247.73% | -55.13% |
Benchmark Metrics
Galera Therapeutics, Inc. has an annualized alpha of -0.96%, beta of 0.80, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 07, 2019.
- This stock participated in 227.55% of S&P 500 Index downside but only 6.21% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.96%
- Beta
- 0.80
- R²
- 0.02
- Upside Capture
- 6.21%
- Downside Capture
- 227.55%
Return for Risk
Risk / Return Rank
GRTX ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Galera Therapeutics, Inc. (GRTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GRTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.44 | ||
| Sortino ratioReturn per unit of downside risk | +0.48 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.37 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 4.82 | 2.78 | +2.04 |
| Martin ratioReturn relative to average drawdown | 10.06 | 12.44 | -2.38 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Galera Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Galera Therapeutics, Inc. was 99.91%, occurring on Sep 9, 2025. The portfolio has not yet recovered.
The current Galera Therapeutics, Inc. drawdown is 99.49%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.91%Sep 2025 | 5y 6mo | — | 6y 3moMar 2020 - now |
2019 bear market2019 | -34.32%Dec 2019 | 21d | 22d | 1mo 13dNov 2019 - Jan 2020 |
2020 bear market2020 | -25.30%Jan 2020 | 19d | 25d | 1mo 14dJan 2020 - Feb 2020 |
2019 correction2019 | -11.02%Nov 2019 | 0s | 4d | 4dNov 2019 - Nov 2019 |
COVID crash2020 | -7.38%Feb 2020 | 0s | 3d | 3dFeb 2020 - Feb 2020 |
Drawdown Indicators
| GRTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -56.78% | -43.13% |
Max Drawdown (1Y)Largest decline over 1 year | -46.67% | -9.10% | -37.57% |
Max Drawdown (3Y)Largest decline over 3 years | -99.49% | -18.90% | -80.59% |
Max Drawdown (5Y)Largest decline over 5 years | -99.85% | -25.43% | -74.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.49% | -1.80% | -97.69% |
Average DrawdownAverage peak-to-trough decline | -78.95% | -10.71% | -68.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.31% | 2.03% | +20.28% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Galera Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Galera Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GRTX, comparing it with other companies in the Biotechnology industry. Currently, GRTX has a P/E ratio of 0.1. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GRTX in comparison with other companies in the Biotechnology industry. Currently, GRTX has a P/B value of 1.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GRTX
Add Galera Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GRTX